Monash antibodies, Adelaide protein gels
Thursday, 22 January, 2009
Monash University has signed a deal with Danish pathology and cancer diagnostics specialist Dako to develop monoclonal antibodies for cancer research and treatment.
The Monash Antibody Technologies Facility (MATF), opened in September last year, will develop high-affinity antibodies for what it called “global commercialisation opportunities”.
MATF director Alan Sawyer said in a statement that the collaboration was part of the facility’s vision to provide the international research and diagnostics community with the best reagents possible.
Meanwhile, the Adelaide Proteomics Centre has decided to adopt publicly listed Fluorotechnics’ range of 2D gels and dyes for protein detection.
The centre has also agreed to become Fluorotechnics’ Australian reference customer and promote the company’s gels in Australia and internationally.
Five scenarios for the future of Antarctic life
A team of Australian and international researchers have predicted five possible outcomes for how...
Could this biosensor bypass labs with onsite PFAS detection?
La Trobe University has developed a portable biosensor that may allow rapid, onsite detection of...
How a tiny worm changed a decade of scientific thinking
A tiny roundworm has helped University of Queensland scientists rethink the way sensory nerve...
